IL15 and glioblastoma: Furthermore, multimodal imaging showed iNSC delivery of RANTES/IL‐15 in combination with intravenous administration of CAR‐T cells reduced established orthotopic GBM xenografts 2538‐fold within the first week, followed by durable tumor remission through 60 days post‐treatment.